← boardnext 2026-12-31
INSM
Insmed Incorporateddistress 2/10 · well-funded / low risk$105.69-1%today-50% from 52w high
Immunology / Inflammation 1Infectious Disease 1Respiratory 1
Lead: Pulmonary Arterial Hypertension · target Prostacyclin · est. market ~$25B (approx, global)
Revenue
$306M
Liquidity
$1224M
Runway
1.4 yrs
Shares 1y
+3%
Price & events
-34.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-1.6%
1W
+3.5%
1M
-26.5%
3M
-32.3%
6M
+2.2%
1Y
+39.1%
2Y
+336.0%
5Y
+216.2%
All
Overview
- Market Cap
- $22.91B
- Enterprise Value
- $22.87B
- Volume
- 81.07K
- 52 Week Range
- $91.88 – $211
- Total Shares
- 216.75M
- Float Shares
- 198.42M
- Short %
- 8.34%
- % Held by Insiders
- 0.52%
- % Held by Institutions
- 103.70%
- RVOL
- 0.02x
- Beta
- 0.78
Pipeline stages · 4 programs
Treprostinil Palmitil Inhalation Powder
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Brensocatib, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TPIP F2, TPIP F3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-03-16 | Phase 2/3 | Treprostinil Palmitil | Pulmonary Arterial Hypertension | — | active not recruiting |
| 2028-12-28 Estimated 50% readout ~2029-03-13 | Phase 3 | Treprostinil Palmitil Inhalation Powder | Pulmonary Arterial Hypertension | — | recruiting |
| 2028-12-30 Estimated 50% readout ~2029-03-15 | Phase 3 | Treprostinil Palmitil Inhalation Powder | Pulmonary Hypertension, Interstitial Lung Disease | — | recruiting |
| 2031-01-22 Estimated 50% readout ~2031-04-07 | Phase 3 | Treprostinil Palmitil Inhalation Powder | Pulmonary Hypertension, Interstitial Lung Disease | — | not yet recruiting |
| 2026-02-12 | Phase 2 | Brensocatib, Placebo | Hidradenitis Suppurativa | 214 | active not recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11-21 | Phase 3 | ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS) | Mycobacterium Infections, Nontuberculous | 425 | completed |
| 2025-10-25 | Phase 1 | TPIP F2, TPIP F3 | Healthy Volunteers | 42 | completed |
| 2025-03-27 | Phase 2 | Treprostinil Palmitil, Placebo | Pulmonary Arterial Hypertension | 102 | completed |
Catalyst news & presentations · 21
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)ARIKAYCE · sNDA submission pending successful ENCORE resultsSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 3TPIP · Initiate Phase 3 study in PPFSEC 8-K
- second half of 2026Guided 55%readoutPhase 2TPIP · Data from OLE of Phase 2b study in PAHSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutPhase 2brensocatib · Topline data from Phase 2b CEDAR studySEC 8-K
- March or April of 2026readoutPhase 3ARIKAYCE · Topline data from Phase 3 ENCORE studySEC 8-K
- 2026-04-07trial discontinuedbrensocatib · Insmed discontinues brensocatib development in HS.SEC 8-K
- early 2026trial initiationsecondaryPhase 3TPIP · Initiate Phase 3 study in PAHSEC 8-K
- early 2026trial initiationsecondaryPhase 3treprostinil palmitil inhalation powder · Planned Phase 3 trial initiation in PAH.SEC 8-K
- first quarter of 2026readoutPhase 3ARIKAYCE · Topline data from ENCORE trialSEC 8-K
- before end of 2025readoutPhase 2brensocatib · Topline data from Phase 2b BiRCh trialSEC 8-K
- second half of 2025trial initiationsecondaryPhase 3TPIP · Initiate Phase 3 studySEC 8-K
- before the end of 2025trial initiationsecondaryPhase 3treprostinil palmitil inhalation powder · Planned Phase 3 trial initiation in PH-ILD.SEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)brensocatib · Regulatory submissions in EU, UK, and JapanSEC 8-K
- 2025-12-17partnershipINS1148 · Acquired monoclonal antibody INS1148 from Opsidio for respiratory and immunological indications.SEC 8-K
- August 12, 2025PDUFAPDUFAbrensocatib · PDUFA target action dateSEC 8-K
- mid-2025readoutPhase 2TPIP · Topline data from Phase 2 studySEC 8-K
- first half of 2025trial initiationsecondaryINS1201 · First patient dosing anticipatedSEC 8-K
- 2025-02-24fda agreementbrensocatib · FDA does not plan to hold advisory committee meeting for brensocatib NDASEC 8-K
- February 6, 2025filing acceptanceFiled (NDA/BLA)brensocatib · FDA accepted NDA for reviewSEC 8-K
- January 29 through February 1, 2025conferencedata presentationsecondaryPhase 2TPIP · Full data presentation at PVRI Annual World CongressSEC 8-K
Approved drugs (3)
- BRINSUPRIBRENSOCATIB2025 · Prescription
- ARIKAYCE KITAMIKACIN SULFATE2018 · Prescription
- IPLEXMECASERMIN RINFABATE RECOMBINANT2005 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $196 (+86% upside) · 21 analysts
- 2026-07-21BMO CapitalOutperform
- 2026-07-15Wells FargoOverweight
- 2026-07-10GuggenheimBuy
- 2026-06-22Evercore ISI GroupOutperform
- 2026-06-08JP MorganOverweight
- 2026-06-05RBC CapitalOutperform
Competitors — Prostacyclin
- none identified
Recent news
- 2026-07-23Insmed's second-quarter business update will be webcast Aug. 6 - Stock Titan
- 2026-07-22This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
- 2026-07-22JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake - Stock Titan
- 2026-07-21INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
- 2026-07-21This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
- 2026-07-21BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
- 2026-07-21INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
- 2026-07-21BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.